ProBioGen successfully completes development project by delivering recombinant Solulin to PAION for pre-clinical testing
Berlin and Aachen, Germany, 01 September 2005
The cell line specialist ProBioGen AG and the Aachen based PAION Deutschland GmbH announced today the successful completion of a joint development project. After establishing the production process, Berlin based ProBioGen has delivered Solulin for final pre-clinical testing, thereby supporting PAION in the preparation for the first clinical Phase I study of the anticoagulant Solulin. ProBioGen will further be responsible for the manufacturing of GMP material for this study, which is anticipated to start at the end of 2005.
Solulin is a recombinant, soluble version of the human membrane protein thrombomodulin. It acts as a natural modulator of coagulation. The drug is currently being developed for the treatment of thrombotic diseases where the present anticoagulants are ineffective or are perceived to have an unsatisfactory safety profile.
ProBioGen and PAION have already been collaborating closely for several years. "We are very glad to assist PAION with another important step in the production of the active drug substance." said Michael Schlenk, CEO of ProBioGen. "We’ve known each other for several years as true and valued partners. Collaborating also during turbulent biotech years, our relationship became even closer." Within the scope of the Solulin manufacturing process, ProBioGen has already developed the production cell line for PAION.
"We are convinced about the quality and competence of ProBioGen and we are looking forward to our collaboration in the upcoming Phase I." commented Alexander Vos, Managing Director of PAION Deutschland GmbH and COO of PAION AG, on the completion of the development project.